Taxane mechanisms of action: Potential implications for treatment sequencing in metastatic castration-resistant prostate cancer

noticia |

Fitzpatrick J.M., De Wit R.

European Urology 2014 65:6 (1198-1204)

Context In the past few years, there has been a rapid increase in the number of therapies available to treat metastatic castration-resistant prostate cancer (mCRPC). Currently, approved treatments consist of the taxane class of cytotoxic drugs and androgen-targeted therapies. The challenge for clinicians is to decide the best sequence in which to give these therapies to provide the greatest benefit to their patients. Objective To review recent research into the mechanism of action of taxanes in prostate cancer (PCa) cells and the clinical evidence for an interaction between taxanes and androgen-targeted therapies. The implications of these findings for clinical practice are discussed. Evidence acquisition A nonsystematic review of the relevant medical literature between 2004 and the present, in combination with clinical trial data reported at oncology meetings during 2012, was undertaken…(ver más)


1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)